CRISPR-Loaded Phage Compositions for E. coli Resistance Mitigation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating bacterial infections, particularly those caused by Escherichia species, face challenges in effectively targeting and eliminating bacteria due to resistance development and the need for broad-spectrum antimicrobial agents.
Innovation Solution
Development of recombinant bacteriophages engineered with CRISPR-Cas systems and colicin-encoding nucleic acids to target and kill Escherichia species, combined with compositions containing multiple bacteriophages and colicins to enhance efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antimicrobial agents are used to treat bacterial infections, then broad-spectrum coverage is achieved, but bacterial resistance develops reducing treatment efficacy
Solution Approach 1:
The patent combines bacteriophage therapy with CRISPR-Cas systems to create a dual-mechanism antimicrobial approach. The bacteriophage infects and replicates within target bacteria while the CRISPR-Cas system simultaneously targets and destroys bacterial DNA, providing complementary killing mechanisms that reduce resistance development
Solution Approach 2:
The invention creates composite therapeutic agents by integrating bacterial viruses (bacteriophages) with eukaryotic-derived nucleic acid systems (CRISPR-Cas). This composite system leverages the host-specificity of phages combined with the precision gene-editing capability of CRISPR to achieve reliable bacterial elimination
2Reliability
If single bacteriophage therapy is used to target specific bacteria, then specificity is achieved, but resistance development and limited efficacy occur
Solution Approach 1:
The patent engineers bacteriophages to perform multiple functions simultaneously: (1) infecting and replicating within target bacteria, (2) delivering CRISPR-Cas systems to the bacterial cytoplasm, and (3) enabling precise DNA targeting. This multi-functionality enhances both efficacy and resistance mitigation
Solution Approach 2:
The invention implements a nested structure where CRISPR-Cas nucleic acid systems are packaged within the bacteriophage particle. The phage acts as a delivery vehicle that transports the CRISPR machinery into the bacterial cell, creating a hierarchical therapeutic system
3Manufacturing precision
If CRISPR-Cas systems are delivered to bacteria, then precise DNA targeting is achieved, but delivery efficiency and stability are challenged
Solution Approach 1:
The bacteriophage serves as an intermediary that bridges the gap between the therapeutic CRISPR-Cas system and the bacterial target. The phage naturally evolved mechanisms to inject its genetic material into bacteria, and this capability is harnessed to deliver the CRISPR nucleic acids efficiently and stably
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered bacteriophages and colicins demonstrate significant bacterial reduction and resistance mitigation, effectively treating infections and reducing bacterial loads in various infection sites.
Implementation Method 1
a first nucleic acid sequence encoding a first spacer sequence or a crRNA transcribed therefrom, wherein the first spacer sequence is complementary to a target nucleotide sequence from a target gene in a Escherichia species
Implementation Method 2
the recombinant bacteriophage binds to and/or infects Escherichia
Implementation Method 3
described herein is a recombinant bacteriophage comprising a nucleic acid sequence encoding a Colicin 10, Colicin Ib, Colicin U, or Colicin K
Data Source
AI summary
Disclosed here are bacteriophage compositions for Escherichia comprising CRISPR-Cas systems and methods of use thereof.